<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">APY</journal-id>
<journal-id journal-id-type="hwp">spapy</journal-id>
<journal-title>Australasian Psychiatry</journal-title>
<issn pub-type="ppub">1039-8562</issn>
<issn pub-type="epub">1440-1665</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1039856212470502</article-id>
<article-id pub-id-type="publisher-id">10.1177_1039856212470502</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Treatments</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The use of psychotropic agents for the symptoms of obsessive–compulsive disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Brakoulias</surname><given-names>Vlasios</given-names></name>
<aff id="aff1-1039856212470502">Clinical Lecturer, University of Sydney, Sydney Medical School (Nepean), Penrith, NSW, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Starcevic</surname><given-names>Vladan</given-names></name>
<aff id="aff2-1039856212470502">Associate Professor, University of Sydney, Sydney Medical School (Nepean), Penrith, NSW, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Berle</surname><given-names>David</given-names></name>
<aff id="aff3-1039856212470502">Clinical Psychologist, Nepean Anxiety Disorders Clinic, Nepean/Blue Mountains Local Health District,
Penrith, NSW, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Milicevic</surname><given-names>Denise</given-names></name>
<aff id="aff4-1039856212470502">Clinical Psychologist, Nepean Anxiety Disorders Clinic, Nepean/Blue Mountains Local Health District, Penrith, NSW, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Moses</surname><given-names>Karen</given-names></name>
<aff id="aff5-1039856212470502">Clinical Psychologist, Nepean Anxiety Disorders Clinic, Nepean/Blue Mountains Local Health District, Penrith, NSW, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Hannan</surname><given-names>Anthony</given-names></name>
<aff id="aff6-1039856212470502">Clinical Psychologist, Nepean Anxiety Disorders Clinic, Nepean/Blue Mountains Local Health District, Penrith, NSW, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Sammut</surname><given-names>Peter</given-names></name>
<aff id="aff7-1039856212470502">Research Assistant, Department of Psychiatry, Nepean Hospital, Penrith, NSW, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Martin</surname><given-names>Andrew</given-names></name>
<aff id="aff8-1039856212470502">Statistician, NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1039856212470502">Dr Vlasios Brakoulias, Department of Psychiatry, Nepean Hospital, PO Box 63, Penrith, NSW 2751, Australia. Email: <email>vlasios.brakoulias@sydney.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>21</volume>
<issue>2</issue>
<fpage>117</fpage>
<lpage>121</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1039856212470502">
<title>Objective:</title>
<p>To describe the use of psychotropic agents in a sample of subjects with obsessive–compulsive disorder (OCD), and in particular the differences associated with different OCD symptoms.</p>
</sec>
<sec id="section2-1039856212470502">
<title>Method:</title>
<p>A total of 154 subjects participated in a study assessing OCD symptom subtypes, called the Nepean OCD Study. In addition to a comprehensive evaluation of the subjects’ OCD symptoms using the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS), Vancouver Obsessive–Compulsive Inventory (VOCI), and the Sheehan Disability Scale (SDS), the subjects’ medication history was recorded. The association between symptom severity, disability, OCD symptom subtypes and the use of psychotropic agents was examined.</p>
</sec>
<sec id="section3-1039856212470502">
<title>Results:</title>
<p>Psychotropic medication was taken by 93 (60.4%) participants. In the majority of cases (<italic>n</italic>=55, 59.1%), selective serotonin reuptake inhibitors (SSRIs) were taken, and of the SSRIs, the most commonly used agent was escitalopram (<italic>n</italic>=21, 22.6%). Psychotropic agents were more likely to be taken by subjects with higher Y-BOCS and SDS scores. Hoarding was associated with a lower likelihood of psychotropic use, whereas unacceptable/taboo thoughts were associated with an increased likelihood of psychotropic and antipsychotic use.</p>
</sec>
<sec id="section4-1039856212470502">
<title>Conclusion:</title>
<p>Patients with OCD are more likely to be taking psychotropic agents if they have a more severe illness, greater disability and more prominent unacceptable/taboo thoughts.</p>
</sec>
</abstract>
<kwd-group>
<kwd>medication</kwd>
<kwd>obsessive–compulsive disorder</kwd>
<kwd>psychotropic agents</kwd>
<kwd>symptoms</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The use of psychotropic agents in patients with obsessive–compulsive disorder (OCD) is an important area of research. It has been observed that patients with OCD often do not receive optimal treatment with psychotropic agents.<sup><xref ref-type="bibr" rid="bibr1-1039856212470502">1</xref></sup> Treatment guidelines<sup><xref ref-type="bibr" rid="bibr2-1039856212470502">2</xref>,<xref ref-type="bibr" rid="bibr3-1039856212470502">3</xref></sup> recommend selective serotonin reuptake inhibitors (SSRIs) or exposure and response prevention (ERP) as first line. However, treatment response is frequently ineffective,<sup><xref ref-type="bibr" rid="bibr4-1039856212470502">4</xref></sup> and only a small proportion of patients with OCD achieve full remission of symptoms.<sup><xref ref-type="bibr" rid="bibr5-1039856212470502">5</xref></sup></p>
<p>Treatment guidelines do not appear to recognise the heterogeneous symptoms of OCD. Yet, Falret made a distinction between ‘folie du doute’ (madness of doubt) and ‘delire du toucher’ (madness of touch) as early as 1869.<sup><xref ref-type="bibr" rid="bibr6-1039856212470502">6</xref></sup> There have also been many studies<sup><xref ref-type="bibr" rid="bibr7-1039856212470502">7</xref>,<xref ref-type="bibr" rid="bibr8-1039856212470502">8</xref></sup> assessing OCD symptoms with principal components analysis that have revealed four to five fairly consistent OCD symptom dimensions. These OCD symptom dimensions include: (a) hoarding; (b) contamination/cleaning; (c) symmetry/ordering; (d) unacceptable/taboo thoughts; and (e) doubt/checking. The first three symptom dimensions have been consistently replicated, unlike the fourth and fifth symptom dimensions, which have been combined in most studies.<sup><xref ref-type="bibr" rid="bibr7-1039856212470502">7</xref>,<xref ref-type="bibr" rid="bibr8-1039856212470502">8</xref></sup></p>
<p>There is some literature to suggest that the predominant OCD symptom dimension may influence treatment response.<sup><xref ref-type="bibr" rid="bibr9-1039856212470502">9</xref></sup> This evidence is strongest for the hoarding symptom dimension, where most studies have shown that patients with more hoarding symptoms have a poorer response to serotonin reuptake inhibitors.<sup><xref ref-type="bibr" rid="bibr10-1039856212470502">10</xref><xref ref-type="bibr" rid="bibr11-1039856212470502"/>–<xref ref-type="bibr" rid="bibr12-1039856212470502">12</xref></sup> A possible problem with pharmacological treatment may be the lower levels of insight that have been associated with hoarding.<sup><xref ref-type="bibr" rid="bibr13-1039856212470502">13</xref>,<xref ref-type="bibr" rid="bibr14-1039856212470502">14</xref></sup> Some, but not all studies have associated sexual and religious obsessions with a poorer response to pharmacotherapy.<sup><xref ref-type="bibr" rid="bibr10-1039856212470502">10</xref>,<xref ref-type="bibr" rid="bibr15-1039856212470502">15</xref><xref ref-type="bibr" rid="bibr16-1039856212470502"/>–<xref ref-type="bibr" rid="bibr17-1039856212470502">17</xref></sup> However, when sexual and religious obsessions have been combined with aggressive obsessions and checking compulsions, some studies suggest an association with improved response to SSRI treatment.<sup><xref ref-type="bibr" rid="bibr18-1039856212470502">18</xref>,<xref ref-type="bibr" rid="bibr19-1039856212470502">19</xref></sup></p>
<p>The study aimed to report the patterns of psychotropic use among a sample of patients where OCD symptoms were carefully assessed. Considering that hoarding has been associated with poorer insight, it was hypothesised that subjects with predominant hoarding would be less likely to be taking psychotropic agents.</p>
<sec id="section5-1039856212470502" sec-type="methods">
<title>Methods</title>
<sec id="section6-1039856212470502">
<title>Recruitment</title>
<p>This report has resulted from the Nepean OCD Study, conducted in Sydney and several other Australian cities. Participants (<italic>n</italic>=154) were recruited from the Nepean Anxiety Disorders Clinic, OCD support groups, newspaper advertisements and referrals from general practitioners, psychiatrists, clinical psychologists and mental health services. Participants were included if they had a primary diagnosis of OCD which was determined on the basis of a clinician-administered semi-structured interview, the Mini International Neuropsychiatric Interview (MINI),<sup><xref ref-type="bibr" rid="bibr20-1039856212470502">20</xref></sup> and the qualifier that OCD was the condition for which they sought help or which caused the most distress or impairment in functioning. Participants needed to be over the age of 18 years. Demographics of the sample are reported elsewhere.<sup><xref ref-type="bibr" rid="bibr21-1039856212470502">21</xref></sup> Institutional ethics committee approval was obtained prior to commencing the study and all participants provided signed informed consent.</p>
</sec>
<sec id="section7-1039856212470502">
<title>Measures</title>
<p>Participants were assessed via structured clinical interviews and self-report instruments. In this article, we report findings derived from the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS),<sup><xref ref-type="bibr" rid="bibr22-1039856212470502">22</xref></sup> Vancouver Obsessional Compulsive Inventory (VOCI)<sup><xref ref-type="bibr" rid="bibr23-1039856212470502">23</xref></sup> and Sheehan Disability Scale (SDS).<sup><xref ref-type="bibr" rid="bibr24-1039856212470502">24</xref></sup> Participants were also asked the specific question, ‘Are you taking any medication for OCD?’ Answers were recorded on a specially constructed data collection sheet.</p>
<p>OCD symptoms were assessed via the Y-BOCS Symptom Checklist (YBOCS-SC) and VOCI. The YBOCS-SC is a semi-structured interview which includes a comprehensive list of 64 obsessions and compulsions arranged by content into 15 categories. The categories for obsessions are: aggressive; contamination; sexual; hoarding/saving; religious; symmetry/exactness; miscellaneous; and somatic. The categories for compulsions are: cleaning/washing; checking; repeating; counting; ordering/arranging; hoarding/collecting; and miscellaneous. Symptom dimensions were determined by subjecting all categories to principal components analysis (PCA), except for aggressive and miscellaneous. Two items from the aggressive obsessions category were re-classified as ‘unintentional harm’. These were: ‘fear will harm others because not careful enough’ and ‘fear will be responsible for something else terrible happening’. All other items were categorised as ‘impulsive aggression’ obsessions. This method has been used in other studies<sup><xref ref-type="bibr" rid="bibr25-1039856212470502">25</xref>,<xref ref-type="bibr" rid="bibr26-1039856212470502">26</xref></sup> in an attempt to reduce the heterogeneity within the aggressive obsessions category. Similarly, in an attempt to reduce the heterogeneity of the miscellaneous categories,<sup><xref ref-type="bibr" rid="bibr27-1039856212470502">27</xref></sup> only the item ‘mental rituals’ was used.</p>
<p>The VOCI is a 55-item self-report measure of OCD symptoms. This instrument uses a five-point Likert-type scale, with ratings being summed to provide scores on six separate subscales (contamination, checking, obsessions, hoarding, just-right experiences and indecisiveness). The internal consistency, test-retest reliability and convergent and discriminant validity of the VOCI have been reported to be favourable.<sup><xref ref-type="bibr" rid="bibr23-1039856212470502">23</xref></sup></p>
<p>The clinician-administered SDS assesses levels of disability in three domains: work, social life, and family life/home responsibilities using a 10-point scale. It has good psychometric properties when used for assessing disability associated with anxiety disorders.<sup><xref ref-type="bibr" rid="bibr28-1039856212470502">28</xref></sup></p>
</sec>
<sec id="section8-1039856212470502">
<title>Statistical methods</title>
<p>All data were entered into the Statistical Package for the Social Sciences (SPSS) version 17,<sup><xref ref-type="bibr" rid="bibr29-1039856212470502">29</xref></sup> and analysed. Additional analyses were conducted using SAS version 9.2.<sup><xref ref-type="bibr" rid="bibr30-1039856212470502">30</xref></sup> PCA was conducted on the 15 YBOCS-SC categories as described above. The study used the technique for factor loading described by Mataix-Cols et al.<sup><xref ref-type="bibr" rid="bibr10-1039856212470502">10</xref></sup> when analysing the YBOCS-SC. According to this technique, Y-BOCS symptom categories regarded as principal symptoms were given a value of 2, whereas other symptom categories that were currently present were given a value of 1, and when there was no symptom in a given category, it was given a value of 0.</p>
<p>Multiple logistic regression was used to examine the relationship between the use of psychotropic agents (fitted as the outcome variable) and the five YBOCS-SC-derived symptom dimensions (fitted together as covariates). A backwards elimination approach was applied to produce a parsimonious model comprising YBOCS-SC-derived symptom dimensions that remained statistically significant. Correlations were also performed to assess the relationship of symptom dimensions determined by the VOCI and use of psychotropic agents. Results were corrected for multiple comparisons using the False Discovery Rate (FDR).<sup><xref ref-type="bibr" rid="bibr31-1039856212470502">31</xref></sup></p>
</sec>
</sec>
<sec id="section9-1039856212470502" sec-type="results">
<title>Results</title>
<p>More than half (<italic>n</italic>=93, 60.4%) of the sample were taking psychopharmacological agents. Of those treated with psychopharmacotherapy, selective serotonin reuptake inhibitors (SSRI) were used by 55 (59.1%) participants. Other psychopharmacological agents included: second generation antipsychotic medication (<italic>n</italic>=23, 24.7%), serotonin and noradrenalin reuptake inhibitors (SNRI) (<italic>n</italic>=16, 17.2%), tricyclic antidepressants (<italic>n</italic>=15, 16.1%), and benzodiazepines (<italic>n</italic>=12, 12.9%). The psychiatric medications used by participants are presented in detail in <xref ref-type="table" rid="table1-1039856212470502">Table 1</xref>. Of the participants taking medication, only two commenced treatment around the time of the assessment, with all others taking medication for over one month. Seven (4.5%) participants had been treated with pharmacotherapy in the past, but were not on any medication at the time of the assessment.</p>
<table-wrap id="table1-1039856212470502" position="float">
<label>Table 1.</label>
<caption><p>Psychopharmacological agents used by study participants (<italic>n</italic>=93)</p></caption>
<graphic alternate-form-of="table1-1039856212470502" xlink:href="10.1177_1039856212470502-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left"><italic>n</italic></th>
<th align="left">%</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Any SSRI<sup><xref ref-type="table-fn" rid="table-fn2-1039856212470502">a</xref></sup></bold></td>
<td>55</td>
<td>59.1</td>
</tr>
<tr>
<td> Escitalopram</td>
<td>21</td>
<td>22.6</td>
</tr>
<tr>
<td> Fluoxetine</td>
<td>13</td>
<td>14.0</td>
</tr>
<tr>
<td> Sertraline</td>
<td>12</td>
<td>12.9</td>
</tr>
<tr>
<td> Fluvoxamine</td>
<td>8</td>
<td>8.6</td>
</tr>
<tr>
<td> Citalopram</td>
<td>7</td>
<td>7.5</td>
</tr>
<tr>
<td> Paroxetine</td>
<td>4</td>
<td>4.3</td>
</tr>
<tr>
<td><bold>Any SNRI</bold></td>
<td><bold>16</bold></td>
<td><bold>17.2</bold></td>
</tr>
<tr>
<td> Venlafaxine</td>
<td>11</td>
<td>11.8</td>
</tr>
<tr>
<td> Duloxetine</td>
<td>5</td>
<td>5.4</td>
</tr>
<tr>
<td><bold>Any NASSA</bold></td>
<td><bold>7</bold></td>
<td><bold>7.5</bold></td>
</tr>
<tr>
<td> Mirtazapine</td>
<td>7</td>
<td>7.5</td>
</tr>
<tr>
<td><bold>Any TCA</bold></td>
<td><bold>15</bold></td>
<td><bold>16.1</bold></td>
</tr>
<tr>
<td> Clomipramine</td>
<td>11</td>
<td>11.8</td>
</tr>
<tr>
<td> Other TCA</td>
<td>4</td>
<td>4.3</td>
</tr>
<tr>
<td><bold>Any second generation antipsychotic agent<sup><xref ref-type="table-fn" rid="table-fn2-1039856212470502">a</xref></sup></bold></td>
<td><bold>23</bold></td>
<td><bold>24.7</bold></td>
</tr>
<tr>
<td> Quetiapine</td>
<td>11</td>
<td>11.8</td>
</tr>
<tr>
<td> Olanzapine</td>
<td>7</td>
<td>7.5</td>
</tr>
<tr>
<td> Paliperidone</td>
<td>3</td>
<td>3.2</td>
</tr>
<tr>
<td> Risperidone</td>
<td>3</td>
<td>3.2</td>
</tr>
<tr>
<td> Aripiprazole</td>
<td>2</td>
<td>2.2</td>
</tr>
<tr>
<td> Clozapine</td>
<td>1</td>
<td>1.1</td>
</tr>
<tr>
<td><bold>Any first generation antipsychotic agent</bold></td>
<td><bold>1</bold></td>
<td><bold>1.1</bold></td>
</tr>
<tr>
<td> Haloperidol</td>
<td>1</td>
<td>1.1</td>
</tr>
<tr>
<td><bold>Any benzodiazepine</bold></td>
<td><bold>12</bold></td>
<td><bold>12.9</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1039856212470502">
<p>SSRI = Selective Serotonin Reuptake Inhibitor; SNRI = Serotonin Noradrenaline Reuptake Inhibitor; NASSA = Noradrenaline-Serotonin Specific Antidepressant; TCA = Tricyclic Antidepressant.</p>
</fn>
<fn id="table-fn2-1039856212470502">
<label>a</label>
<p>Some participants were taking more than one SSRI and more than one second-generation antipsychotic agent.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The use of any psychotropic agents was associated with greater severity of OCD, as measured by the Y-BOCS total score (<italic>r</italic>=0.235, <italic>p</italic>=0.004), and higher rates of disability in the work (<italic>r</italic>=0.394, <italic>p</italic>=0.000) and social domain (<italic>r</italic>=0.307, <italic>p</italic>=0.000), as measured by the SDS.</p>
<p>Using the YBOCS-SC, higher scores on the hoarding symptom factor predicted a lower likelihood of taking any psychotropic agent, and higher scores on the unacceptable/taboo thoughts factor predicted a greater likelihood of taking any psychotropic agent (<xref ref-type="table" rid="table2-1039856212470502">Table 2</xref>). Correlations using the VOCI produced similar results (<xref ref-type="table" rid="table3-1039856212470502">Table 3</xref>), with the additional finding that VOCI obsessions were correlated with higher rates of antipsychotic usage (<italic>r</italic>=0.226, <italic>p</italic>=0.006).</p>
<table-wrap id="table2-1039856212470502" position="float">
<label>Table 2.</label>
<caption><p>Logistic regression analysis of the association between YBOCS-SC-derived OCD symptom dimensions and the use of any psychotropic agent (<italic>n</italic>=154)</p></caption>
<graphic alternate-form-of="table2-1039856212470502" xlink:href="10.1177_1039856212470502-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Odds ratio</th>
<th align="left">95% confidence interval</th>
<th align="left"><italic>P</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Hoarding</bold></td>
<td>0.54</td>
<td>0.34–0.83</td>
<td>0.0057</td>
</tr>
<tr>
<td><bold>Contamination/cleaning</bold></td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td><bold>Symmetry/ordering</bold></td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td><bold>Unacceptable/taboo thoughts</bold></td>
<td>4.46</td>
<td>1.45–13.70</td>
<td>0.0091</td>
</tr>
<tr>
<td><bold>Doubt/checking</bold></td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1039856212470502">
<p>ns = not statistically significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1039856212470502" position="float">
<label>Table 3.</label>
<caption><p>Correlations between VOCI symptom sub-scores and psychotropic use (<italic>n</italic>=154)</p></caption>
<graphic alternate-form-of="table3-1039856212470502" xlink:href="10.1177_1039856212470502-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Any psychotropic agent</th>
<th align="left">Any SSRI</th>
<th align="left">Any anti-psychotic agent<sup><xref ref-type="table-fn" rid="table-fn4-1039856212470502">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>VOCI Contamination</bold></td>
<td><italic>p</italic>= .021, <italic>r</italic>= .192</td>
<td><italic>p</italic>= .019, <italic>r</italic>= .194</td>
<td><italic>p</italic>= .214, <italic>r</italic>= .104</td>
</tr>
<tr>
<td><bold>VOCI Checking</bold></td>
<td><italic>p</italic>= .497, <italic>r</italic>= .057</td>
<td><italic>p</italic>= .124, <italic>r</italic>= .128</td>
<td><italic>p</italic>= .241, <italic>r</italic>= .098</td>
</tr>
<tr>
<td><bold>VOCI Obsessions</bold></td>
<td><italic>p</italic>= .000<xref ref-type="table-fn" rid="table-fn4-1039856212470502">*</xref>, <italic>r</italic>= .302</td>
<td><italic>p</italic>= .036, <italic>r</italic>= .174</td>
<td><italic>p</italic>= .006<xref ref-type="table-fn" rid="table-fn4-1039856212470502">*</xref>, <italic>r</italic>= .226</td>
</tr>
<tr>
<td><bold>VOCI Hoarding</bold></td>
<td><italic>p</italic>= .027, <italic>r</italic>= -.184</td>
<td><italic>p</italic>= .882, <italic>r</italic>= .012</td>
<td><italic>p</italic>= .459, <italic>r</italic>= -.062</td>
</tr>
<tr>
<td><bold>VOCI Just Right</bold></td>
<td><italic>p</italic>= .109, <italic>r</italic>= .133</td>
<td><italic>p</italic>= .020, <italic>r</italic>= .193</td>
<td><italic>p</italic>= .146, <italic>r</italic>= .121</td>
</tr>
<tr>
<td><bold>VOCI Indecisiveness</bold></td>
<td><italic>p</italic>= .065, <italic>r</italic>= .153</td>
<td><italic>p</italic>= .062, <italic>r</italic>= .155</td>
<td><italic>p</italic>= .043, <italic>r</italic>= .169</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1039856212470502">
<label>a</label>
<p>Includes both 1<sup>st</sup> and 2<sup>nd</sup> generation anti-psychotics, *Significant after correction for multiple comparisons (<italic>p</italic>&lt;0.007).</p>
</fn>
<fn id="table-fn5-1039856212470502">
<p>VOCI: Vancouver Obsessive–Compulsive Inventory</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-1039856212470502" sec-type="discussion">
<title>Discussion</title>
<p>This study shows that subjects with predominant hoarding symptoms were less likely to be taking psychotropic medication and that subjects with predominant unacceptable/taboo symptoms were more likely to be taking psychotropic medication. The lower likelihood of any psychotropic use in subjects with predominant hoarding may result from the low levels of insight that have been associated with hoarding.<sup><xref ref-type="bibr" rid="bibr13-1039856212470502">13</xref>,<xref ref-type="bibr" rid="bibr14-1039856212470502">14</xref></sup> Low levels of insight are likely to be associated with reduced treatment-seeking and adherence to any treatment. The finding in relation to unacceptable/taboo thoughts requires replication. In contrast to hoarding symptoms that are relatively ego-syntonic, unacceptable/taboo thoughts are ego-dystonic. The levels of distress associated with unacceptable/taboo thoughts may be a significant motivating factor for seeking treatment. This is supported by one study<sup><xref ref-type="bibr" rid="bibr32-1039856212470502">32</xref></sup> that showed that impulsive aggression obsessions and other unpleasant thoughts were associated with higher rates of treatment-seeking.</p>
<p>Increased OCD severity and OCD-related disability are also likely to be significant motivating factors to seek treatment and use psychotropic medication, thus explaining the finding of increased psychotropic use in those subjects with greater severity and OCD-related disability. The use of antipsychotic agents in OCD subjects may be another indicator of greater levels of distress and increased treatment-seeking. Subjects with more prominent unacceptable/taboo thoughts may be using more antipsychotic agents due to greater levels of distress and/or treatment-seeking. Subjects taking antipsychotic agents may also be perceived as treatment-resistant or needing more medication (antipsychotic in addition to an antidepressant).</p>
<p>The study is limited in that it does not represent an empirical investigation of treatment response. There are too many confounding factors to draw meaningful conclusions regarding the effectiveness of psychotropic agents taken by patients in this sample. Information regarding the extent of compliance was not recorded and the study would have been enhanced by including a measure of treatment adherence. Patients may not have been taking what they had been prescribed, and hence findings may not accurately reflect prescribing practices. It should also be noted that not all subjects had seen a medical practitioner for their OCD prior to assessment.</p>
</sec>
<sec id="section11-1039856212470502" sec-type="conclusions">
<title>Conclusions</title>
<p>Patients with OCD have different patterns of psychotropic usage depending on their symptoms, the severity of these symptoms and their associated levels of disability. This adds to evidence supporting symptom-based approaches to understanding the heterogeneity of OCD.</p>
</sec>
</body>
<back>
<ack>
<p>The authors are grateful to Colin Slocombe from ACEDA Adelaide, Michelle Graeber from ARCVIC Melbourne, Scott Blair-West of the Melbourne Clinic, the Blacktown and Kogarah OCD Support Groups, the Mental Health Association of NSW and the Penrith Mental Health Practitioners’ Network.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The study was funded by the Nepean Medical Research foundation, a competitive Pfizer Neuroscience Grant and a grant from the Discipline of Psychiatry at The University of Sydney.</p>
</fn>
<fn fn-type="conflict">
<label>Disclosure</label>
<p>The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1039856212470502">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Denys</surname><given-names>D</given-names></name>
<name><surname>Van Megen</surname><given-names>H</given-names></name>
<name><surname>Westenberg</surname><given-names>H</given-names></name>
</person-group>. <article-title>The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder</article-title>. <source>Int Clin Psychopharmacol</source> <year>2002</year>; <volume>17</volume>: <fpage>109</fpage>.</citation>
</ref>
<ref id="bibr2-1039856212470502">
<label>2.</label>
<citation citation-type="book">
<article-title>Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder</article-title>. In: <source>Clinical Guideline 31</source>. <publisher-loc>London</publisher-loc> <publisher-name>National Institute for Health and Clinical Excellence (NICE)</publisher-name>, <year>2005</year>, pp. <fpage>10</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr3-1039856212470502">
<label>3.</label>
<citation citation-type="book">
<article-title>Treatment of patients with obsessive-compulsive disorder</article-title>. In: <source>American Psychiatric Association practice guidelines</source>. <publisher-name>American Psychiatric Association</publisher-name>, <year>2007</year>, pp. <fpage>5</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr4-1039856212470502">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schruers</surname><given-names>K</given-names></name>
<name><surname>Koning</surname><given-names>K</given-names></name>
<name><surname>Luermans</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Obsessive-compulsive disorder: a critical review of therapeutic perspectives</article-title>. <source>Acta Psychiatr Scand</source> <year>2005</year>; <volume>111</volume>: <fpage>261</fpage>–<lpage>271</lpage>.</citation>
</ref>
<ref id="bibr5-1039856212470502">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eisen</surname><given-names>JL</given-names></name>
<name><surname>Goodman</surname><given-names>WK</given-names></name>
<name><surname>Keller</surname><given-names>MB</given-names></name>
<etal/></person-group>. <article-title>Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study</article-title>. <source>J clin psychiatr</source> <year>1999</year>; <volume>60</volume>: <fpage>346</fpage>.</citation>
</ref>
<ref id="bibr6-1039856212470502">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hantouche</surname><given-names>EG</given-names></name>
<name><surname>Lancrenon</surname><given-names>S</given-names></name>
</person-group>. <article-title>Modern typology of symptoms and obsessive-compulsive syndromes: results of a large French study of 615 patients</article-title>. <source>‘Encéphale</source> <year>1996</year>; <volume>22</volume> Spec No 1: <fpage>9</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr7-1039856212470502">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bloch</surname><given-names>MH</given-names></name>
<name><surname>Landeros-Weisenberger</surname><given-names>A</given-names></name>
<name><surname>Rosario</surname><given-names>MC</given-names></name>
<etal/></person-group>. <article-title>Meta-analysis of the symptom structure of obsessive-compulsive disorder</article-title>. <source>Am J Psychiatr</source> <year>2008</year>; <volume>165</volume>: <fpage>1532</fpage>–<lpage>1542</lpage>.</citation>
</ref>
<ref id="bibr8-1039856212470502">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mataix-Cols</surname><given-names>D</given-names></name>
<name><surname>Rosario-Campos</surname><given-names>MC</given-names></name>
<name><surname>Leckman</surname><given-names>JF</given-names></name>
</person-group>. <article-title>A multidimensional model of obsessive-compulsive disorder</article-title>. <source>Am J Psychiatr</source> <year>2005</year>; <volume>162</volume>: <fpage>228</fpage>–<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr9-1039856212470502">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Starcevic</surname><given-names>V</given-names></name>
<name><surname>Brakoulias</surname><given-names>V</given-names></name>
</person-group>. <article-title>Symptom subtypes of obsessive–compulsive disorder: are they relevant for treatment?</article-title> <source>Aust New Zeal J Psychiatr</source> <year>2008</year>; <volume>42</volume>: <fpage>651</fpage>–<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr10-1039856212470502">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mataix-Cols</surname><given-names>D</given-names></name>
<name><surname>Rauch</surname><given-names>SL</given-names></name>
<name><surname>Manzo</surname><given-names>PA</given-names></name>
<etal/></person-group>. <article-title>Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder</article-title>. <source>Am J Psychiatr</source> <year>1999</year>; <volume>156</volume>: <fpage>1409</fpage>–<lpage>1416</lpage>.</citation>
</ref>
<ref id="bibr11-1039856212470502">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Samuels</surname><given-names>J</given-names></name>
<name><surname>Bienvenu</surname><given-names>O</given-names></name>
<name><surname>Riddle</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Hoarding in obsessive compulsive disorder: results from a case-control study</article-title>. <source>Behav Res Ther</source> <year>2002</year>; <volume>40</volume>: <fpage>517</fpage>–<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr12-1039856212470502">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stein</surname><given-names>DJ</given-names></name>
<name><surname>Carey</surname><given-names>PD</given-names></name>
<name><surname>Lochner</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy</article-title>. <source>CNS Spectrums</source> <year>2008</year>; <volume>13</volume>: <fpage>492</fpage>–<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr13-1039856212470502">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Samuels</surname><given-names>JF</given-names></name>
<name><surname>Bienvenu</surname><given-names>O</given-names></name>
<name><surname>Pinto</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Hoarding in obsessive–compulsive disorder: results from the OCD Collaborative Genetics Study</article-title>. <source>Behav Res Ther</source> <year>2007</year>; <volume>45</volume>: <fpage>673</fpage>–<lpage>686</lpage>.</citation>
</ref>
<ref id="bibr14-1039856212470502">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Damecour</surname><given-names>CL</given-names></name>
<name><surname>Charron</surname><given-names>M</given-names></name>
</person-group>. <article-title>Hoarding: a symptom, not a syndrome</article-title>. <source>J Clin Psychiatr</source> <year>1998</year>; <volume>59</volume>: <fpage>267</fpage>–<lpage>272</lpage>; quiz 273.</citation>
</ref>
<ref id="bibr15-1039856212470502">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>P</given-names></name>
<name><surname>Menchon</surname><given-names>JM</given-names></name>
<name><surname>Pifarre</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy</article-title>. <source>J Clin Psychiatr</source> <year>2001</year>; <volume>62</volume>: <fpage>535</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr16-1039856212470502">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erzegovesi</surname><given-names>S</given-names></name>
<name><surname>Cavallini</surname><given-names>MC</given-names></name>
<name><surname>Cavedini</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Clinical predictors of drug response in obsessive-compulsive disorder</article-title>. <source>J Clin Psychopharmacol</source> <year>2001</year>; <volume>21</volume>: <fpage>488</fpage>–<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr17-1039856212470502">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Denys</surname><given-names>D</given-names></name>
<name><surname>Burger</surname><given-names>H</given-names></name>
<name><surname>van Megen</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>A score for predicting response to pharmacotherapy in obsessive-compulsive disorder</article-title>. <source>Int Clin Psychopharmacol</source> <year>2003</year>; <volume>18</volume>: <fpage>315</fpage>.</citation>
</ref>
<ref id="bibr18-1039856212470502">
<label>18.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Eisen</surname><given-names>J</given-names></name>
<name><surname>Greenberg</surname><given-names>B</given-names></name>
<name><surname>Mancebo</surname><given-names>M</given-names></name>
<etal/></person-group>. <source>OCD Subtypes</source>. <publisher-loc>Toronto, CA</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>, <year>2006</year>.</citation>
</ref>
<ref id="bibr19-1039856212470502">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landeros-Weisenberger</surname><given-names>A</given-names></name>
<name><surname>Bloch</surname><given-names>MH</given-names></name>
<name><surname>Kelmendi</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder</article-title>. <source>J Affect Disord</source> <year>2010</year>; <volume>121</volume>: <fpage>175</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr20-1039856212470502">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sheehan</surname><given-names>DV</given-names></name>
<name><surname>Lecrubier</surname><given-names>Y</given-names></name>
<name><surname>Sheehan</surname><given-names>KH</given-names></name>
<etal/></person-group>. <article-title>The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title>. <source>J Clin Psychiatr</source> <year>1998</year>; <volume>59</volume> <supplement>Suppl 20</supplement>: <fpage>22</fpage>–<lpage>33</lpage>; quiz 34–57.</citation>
</ref>
<ref id="bibr21-1039856212470502">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Starcevic</surname><given-names>V</given-names></name>
<name><surname>Berle</surname><given-names>D</given-names></name>
<name><surname>Brakoulias</surname><given-names>V</given-names></name>
<etal/></person-group>. <article-title>The nature and correlates of avoidance in obsessive–compulsive disorder</article-title>. <source>Aust New Zeal J Psychiatr</source> <year>2011</year>; <volume>45</volume>: <fpage>871</fpage>–<lpage>879</lpage>.</citation>
</ref>
<ref id="bibr22-1039856212470502">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goodman</surname><given-names>WK</given-names></name>
<name><surname>Price</surname><given-names>LH</given-names></name>
<name><surname>Rasmussen</surname><given-names>SA</given-names></name>
<etal/></person-group>. <article-title>The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability</article-title>. <source>Arch Gen Psychiatr</source> <year>1989</year>; <volume>46</volume>: <fpage>1006</fpage>–<lpage>1011</lpage>.</citation>
</ref>
<ref id="bibr23-1039856212470502">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thordarson</surname><given-names>DS</given-names></name>
<name><surname>Radomsky</surname><given-names>AS</given-names></name>
<name><surname>Rachman</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>The Vancouver Obsessional Compulsive Inventory (VOCI)</article-title>. <source>Behav Res Ther</source> <year>2004</year>; <volume>42</volume>: <fpage>1289</fpage>–<lpage>1314</lpage>.</citation>
</ref>
<ref id="bibr24-1039856212470502">
<label>24.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Sheehan</surname><given-names>D</given-names></name>
</person-group>. <source>The Sheehan disability scales</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Charles Scribner and Sons</publisher-name>., <year>1983</year>.</citation>
</ref>
<ref id="bibr25-1039856212470502">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinto</surname><given-names>A</given-names></name>
<name><surname>Greenberg</surname><given-names>BD</given-names></name>
<name><surname>Grados</surname><given-names>MA</given-names></name>
<etal/></person-group>. <article-title>Further development of YBOCS dimensions in the OCD Collaborative Genetics Study: symptoms vs. categories</article-title>. <source>Psychiatr Res</source> <year>2008</year>; <volume>160</volume>: <fpage>83</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr26-1039856212470502">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinto</surname><given-names>A</given-names></name>
<name><surname>Eisen</surname><given-names>JL</given-names></name>
<name><surname>Mancebo</surname><given-names>MC</given-names></name>
<etal/></person-group>. <article-title>Taboo thoughts and doubt/checking: a refinement of the factor structure for obsessive–compulsive disorder symptoms</article-title>. <source>Psychiatr Res</source> <year>2007</year>; <volume>151</volume>: <fpage>255</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr27-1039856212470502">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>MT</given-names></name>
<name><surname>Farris</surname><given-names>SG</given-names></name>
<name><surname>Turkheimer</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Myth of the pure obsessional type in obsessive–compulsive disorder</article-title>. <source>Depress Anxiety</source> <year>2011</year>; <volume>28</volume>: <fpage>495</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr28-1039856212470502">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hambrick</surname><given-names>JP</given-names></name>
<name><surname>Turk</surname><given-names>CL</given-names></name>
<name><surname>Heimberg</surname><given-names>RG</given-names></name>
<etal/></person-group>. <article-title>Psychometric properties of disability measures among patients with social anxiety disorder</article-title>. <source>J Anxiety Disord</source> <year>2004</year>; <volume>18</volume>: <fpage>825</fpage>–<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr29-1039856212470502">
<label>29.</label>
<citation citation-type="book">
<collab>I.B.M. SPSS Statistics 17.0.</collab> <publisher-loc>Chicago, Illinois</publisher-loc>: <publisher-name>SPSS Inc</publisher-name>, <year>2003</year>.</citation>
</ref>
<ref id="bibr30-1039856212470502">
<label>30.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Allison</surname><given-names>PD</given-names></name>
</person-group>. <source>Survival analysis using SAS: a practical guide</source>. <publisher-loc>Cary, NC</publisher-loc>: <publisher-name>SAS publishing</publisher-name>, <year>2010</year>.</citation>
</ref>
<ref id="bibr31-1039856212470502">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamini</surname><given-names>Y</given-names></name>
<name><surname>Hochberg</surname><given-names>Y</given-names></name>
</person-group>. <article-title>On the adaptive control of the false discovery rate in multiple testing with independent statistics</article-title>. <source>J Educ Behav Stat</source> <year>2000</year>; <volume>25</volume>: <fpage>60</fpage>.</citation>
</ref>
<ref id="bibr32-1039856212470502">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayerovitch</surname><given-names>JI</given-names></name>
<name><surname>du Fort</surname><given-names>GG</given-names></name>
<name><surname>Kakuma</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Treatment seeking for obsessive-compulsive disorder: role of obsessive-compulsive disorder symptoms and comorbid psychiatric diagnoses</article-title>. <source>Compr Psychiatr</source> <year>2003</year>; <volume>44</volume>: <fpage>162</fpage>–<lpage>168</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>